Retrospective Cohort Study
Copyright ©The Author(s) 2022.
World J Clin Cases. Nov 6, 2022; 10(31): 11325-11337
Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11325
Table 1 Baseline characteristics of unmatched and matched cohort
VariableUnmatched cohort
Matched cohort
Cirrhosis, n = 28
Noncirrhosis, n = 537
P value
Cirrhosis, n = 25
Noncirrhosis, n = 75
P value
Sex, male22 (78.6)373 (69.5)0.30519 (76.0)56 (74.7)0.894
Age, yr (SD)59.8 (8.2)62.5 (7.9)0.08159.3 (8.5)60.8 (8.3)0.424
Location0.0270.427
Upper3 (10.7)42 (7.8)2 (8.0)2 (2.7)
Middle12 (42.9)360 (67.0)14 (56.0)42 (56.0)
Lower13 (46.4)135 (25.2)9 (36.0)31 (41.3)
Circumference0.2000.637
> 1/2, < 3/416 (57.1)369 (68.7)14 (56.0)46 (61.3)
≥ 3/412 (42.9)168 (31.3)11 (44.0)29 (38.7)
Macroscopic type[20]< 0.010.137
IIa + IIb/Is/IIa4 (14.3)281 (52.3)6 (24.0)7 (9.3)
IIb14 (50.0)231 (43.0)13 (52.0)52 (69.3)
IIb + IIc/IIc/IIa + IIc10 (35.7)25 (4.7)6 (24.0)16 (21.4)
Area, cm2 (SD)113.5 (6.7)13.8 (9.6)0.82814.1 (6.9)13.6 (8.9)0.810
Invasion depth0.3791.000
EP/LPM23 (82.1)471 (87.7)21 (84.0)62 (82.7)
MM/SM15 (17.9)66 (12.3)4 (16.0)13 (17.3)
Table 2 Characteristics of early esophageal squamous cell carcinoma patients with comorbid liver cirrhosis1
Cirrhosis group characteristics
Value
Cause of liver cirrhosis
Hepatitis B9 (36.0)
Hepatitis C1 (4.0)
Alcohol13 (52.0)
Autoimmune hepatitis2 (8.0)
Ascitic fluid
No14 (56.0)
Yes11 (44.0)
Total bilirubin, μmol/L (SD)21.0 (9.6)
Albumin, g/L (SD)38.0 (5.6)
Prothrombin time, s (SD)12.9 (1.7)
Child-Pugh score13, n (SD)6.0 (1.3)
Child-pugh classification[13]
A15 (60.0)
B9 (36.0)
C1 (4.0)
Esophageal varices and grade[14]
Yes, mild esophageal varices4 (16.0)
Yes, severe esophageal varices6 (24.0)
No15 (60.0)
Gastric varices and Sarin type[21]
Yes, GOV-13 (12.0)
Yes, GOV-21 (4.0)
Yes, IGV1 (4.0)
No20 (80.0)
EVL3
ETAI1
TIPS3
Lesions on esophageal varices
Yes4 (16.0)
No21 (84.0)
Table 3 Endoscopic efficacy and safety in patients with or without liver cirrhosis underwent endoscopic submucosal tunnel dissection
Clinical data
Cirrhosis (n = 25)
Noncirrhosis (n = 75)
P value
Number of tunnels0.430
Single tunnel17 (68.0)57 (76.0)
Multiple tunnels8 (32.0)18 (24.0)
R0 resection22 (88.0)65 (86.7)1.000
Curative resection19 (76.0)57 (76.0)1.000
Dissection speed, mm²/min (SD)24.5 (11.6)21(11.8)0.200
Intraoperative bleeding12 (48.0)26 (34.7)0.234
30-d post-ESTD bleeding2 (8.0)0 (0)0.099
Muscular injury5 (20.0)23 (30.7)0.304
Prednisone used post-ESTD5 (20.0)18 (24.0)0.681
Stenosis2 (8.0)12 (16.0)0.506
Perforation0 (0)3 (4.0)0.735
Post-ESTD fever11 (44.0)21 (28.0)0.137
Post-ESTD pneumonia2 (8.0)16 (21.3)0.229
Hospitalization, day (SD)14.9 (7.5)10.3 (4.5)0.007
Post-ESTD duration, d (SD)6.5 (2.9)6.1 (2.9)0.523
Hospitalization costs, $ (SD)4985.9 (1815.7)4083.8 (759.0)0.023
Median follow-up time, months45390.430
Local Recurrence1 (4)3 (4)1.000
OS17 (68.0)71 (94.7)0.001
DSS24 (96.0)75 (100.0)0.075
RFS24 (96.0)72 (96.0)0.8196